Sequella

Sequella is a biotechnology company dedicated to developing novel antibiotics to combat drug-resistant infections, particularly tuberculosis and its various resistant forms. Founded in 1997 and headquartered in Rockville, US, Sequella focuses on antibiotic innovation. The company is led by CEO Carol Nacy and co-founder Leo Einck. Since its inception, Sequella has engaged in 11 deals, with its most recent funding round occurring in October 2013, raising USD 0.

55 mn. Sequella develops antibiotics targeting drug-resistant infections, with a primary focus on tuberculosis (TB), including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. Its lead candidates, SQ109 and sutezolid, have completed phase 2 clinical trials. The company also addresses other health challenges such as Helicobacter pylori and Clostridium difficile infections, with additional candidates like SQ641 in preclinical stages, aiming to alleviate global health burdens affecting over 3 billion people, especially in high TB-prevalence areas like sub-Saharan Africa and Southeast Asia.

Sequella operates through partnerships and licensing agreements with pharmaceutical companies and research organizations for the development and commercialization of its antibiotic products. The business model focuses on business-to-business transactions, licensing drug candidates, and securing milestones and royalties from successful clinical trials and product sales. One example includes Sequella's agreement with LabCorp for the B-SMART™ technology, which aligns with its strategy to leverage proprietary innovations while accessing the diagnostic market. Sequella plans to utilize the USD 0.

55 mn raised in October 2013 to support upcoming product developments and expand its market reach. The company is focused on advancing its lead products and exploring new antibiotic candidates, with an eye towards entering additional markets in sub-Saharan Africa and Southeast Asia by 2025. Continued collaboration with pharmaceutical and research partners will be key to achieving these growth objectives.